{"Content: ":"Somatrogon, sold under the brand name Ngenla, is a medication for the treatment of growth hormone deficiency.[1][4] Somatrogon is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal.[4] The most common side effects include reactions at the site of injection, headache, and fever.[3] Somatrogon was approved for medical use in Australia in November 2021,[1] and in the European Union in February 2022.[3] On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ngenla, intended for the treatment of growth hormone deficiency (GHD) in children and adolescents from three years of age.[5] The applicant for this medicinal product is Pfizer Europe MA EEIG.[5] Somatrogon was approved for medical use in the European Union in February 2022.[3] Somatrogon is the international nonproprietary name (INN).[6] Antagonists: Pegvisomant  This hormonal preparation article is a stub. You can help Wikipedia by expanding it.","Title":"Somatrogon - Wikipedia","KeyID":"8067","URL":"https://en.wikipedia.org/wiki/Somatrogon"}